Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling.
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
